Home > Insider Trading > Filing (0001298711-23-000017)

Filing Details

Accession Number:: 0001298711-23-000017
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-12 18:01:01
Reporting Period:: 2023-09-11

Accepted Time:: 2023-09-12 18:01:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1711279	Krystal Biotech Inc.	KRYS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1298711	Suma Krishnan	C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203	President, R&D	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-11	5,007	$125.23	1,619,199	No	4	S	Direct
Common Stock	Disposition	2023-09-11	5,452	$126.17	1,613,747	No	4	S	Direct
Common Stock	Disposition	2023-09-11	1,874	$127.18	1,611,873	No	4	S	Direct
Common Stock	Disposition	2023-09-11	10,557	$128.37	1,601,316	No	4	S	Direct
Common Stock	Disposition	2023-09-11	2,110	$129.10	1,599,206	No	4	S	Direct
Common Stock	Disposition	2023-09-11	5,008	$125.23	1,679,330	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-11	5,452	$126.17	1,673,878	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-11	1,873	$127.18	1,672,005	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-11	10,557	$128.37	1,661,448	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2023-09-11	2,110	$129.10	1,659,338	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	90,000	Indirect	By SMK Trust
Common Stock	50,000	Indirect	By Krishnan Family Trust

Footnotes

The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
The transaction was executed in multiple trades ranging from $124.7100 to $125.6950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $125.7200 to $126.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $126.7200 to $127.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $127.7350 to $128.7300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $128.7400 to $129.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on September 11, 2023, and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.